Earningsreport

Q4/2023 12/31/2023 EPS -0.840 ZacksConsensus -0.880 ActVsEst 0.040 - Beat

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com